GERMANTOWN, Md. – Sept. 10, 2019 – PRLog — Primetime Life Sciences, LLC, a Maryland based pharmaceutical company focused on discovery and development of new and smart treatments, announced today that the company has successfully met the Phase I grant milestones, and has been awarded Phase II funding of $2.63 million from a Fast Track Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH). The SBIR program supports scientific excellence and technological innovation by encouraging small businesses to engage in translation research and bring innovative treatments.
{iframe}https://www.biospace.com/article/primetime-life-sciences-approved-for-2-63-million-phase-ii-fast-track-sbir-grant/{/iframe}